ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million Management to Host
DURHAM, N.C. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will participate in a pre-recorded
FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021 DURHAM, N.C. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S.
DURHAM, N.C. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview and
– C ompleted R olling NDA S ubmissions for Both BCV Tablet and S uspension Formulations as M edical C ountermeasure for S mallpox – – F irst Patient Visit for DSTAT Phase 3 AML Study Expected in Early 2021 – – C ompany Well Capitalized Through Several Expected Upcoming Milestones – – C
DURHAM, N.C. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 5,
DURHAM, N.C. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:
– Completion of BCV NDA Rolling Submission Planned for Third Quarter 2020 – – Currently Enrolling Phase 2/3 Study of DSTAT in Patients with COVID-19; Phase 2 Enrollment Completion Expected in Fourth Quarter – – Startup Activities for DSTAT Phase 3 AML Study Initiated; Site Activation Expected
DURHAM, N.C. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10,
Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise DURHAM, N.C. , June 22, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the
